## Core Concept
Gastrointestinal Stromal Tumors (GISTs) are the most common mesenchymal neoplasms of the gastrointestinal tract. They originate from the interstitial cells of Cajal or their precursors, which are part of the autonomic nervous system of the gut. GISTs are known for their varied presentation and specific genetic mutations.

## Why the Correct Answer is Right
The correct answer, although not directly provided, relates to understanding what is not true about GISTs. Typically, GISTs are characterized by mutations in the KIT gene or the PDGFRA gene, which are crucial for their growth and survival. These tumors are usually resistant to conventional chemotherapy and radiotherapy but respond well to targeted therapy with tyrosine kinase inhibitors like imatinib.

## Why Each Wrong Option is Incorrect
- **Option A:** Without specific details on option A, we can infer that any statement claiming GISTs are primarily treated with conventional chemotherapy or that they are not responsive to targeted therapy would be incorrect. GISTs are known to be resistant to traditional chemotherapy but responsive to targeted therapies.
- **Option B:** Similarly, if option B suggests that GISTs are not associated with specific genetic mutations (like KIT or PDGFRA), this would be incorrect. These mutations are hallmark genetic alterations in GISTs.
- **Option C:** If option C states that GISTs are common in the stomach, this would actually be correct, as the stomach is a common location for GISTs, making this option not the answer to what is "not true."
- **Option D:** Without specifics, if option D claims that GISTs are highly aggressive and have a poor prognosis regardless of treatment, this is partially misleading. While some GISTs can be aggressive, targeted therapy has significantly improved the prognosis for many patients.

## Clinical Pearl / High-Yield Fact
A key point to remember is that **GISTs are often associated with mutations in the KIT or PDGFRA genes**, and **targeted therapy with tyrosine kinase inhibitors (e.g., imatinib) is a cornerstone of treatment**, significantly improving outcomes for patients with these tumors.

## Correct Answer: D. Highly aggressive and do not respond to any treatment.